C. Jillian Tsai, MD, PhD
@CJTsaiMDPhD
Followers
4K
Following
11K
Media
399
Statuses
4K
Lead, Allan & Ruth Kerbel Palliative RT/Oligomet Program (PROP) @PMcancercentre @RadMedPM @UHN. Via @MSKCancerCenter @MDAndersonNews. HN/skin/metastatic cancers
Toronto, ON, Canada
Joined February 2018
🚨📢🌟 CURB2 Ph3 Trial is activated by @NCICTEP_ClinRes (NCT06686771), built upon CURB Ph2 RCT @TheLancet/@MSKCancerCenter. Appreciate the support of @NRGonc/@SWOG/@CCTG. Pls contact us for activation at your local site❗️. @pmcancercentre @ldawsonmd @DrAlexLouie @HoudaBahig
2
11
53
Interesting images for all the HN surgeons!.Frostbite Injury from Inhaled Nitrous Oxide Use | New England Journal of Medicine
0
0
7
👀Not cancer but promising concept/result. As we expand the indication of #radiotherapy this could be an area of active interest. @SameerKeoleMD @ASTRO_org .
6
17
51
🚨Advanced Pract Radiation Therapist🚨.🌟 #APRT @JoannaJavor of Allan & Ruth Kerbel Pall RT/Oligomet Program (PROP) presented data of sim-free RT (incl single fx #SBRT 12-20Gy). Best wishes for her med school pursuit! 🔥.📢📢PS. We will be looking for an #APRT. PM me for details.
0
3
10
Hilarious. 😂.Should add that if p>0.05 some might change endpoint and re-analyze!. This is just unthinkable when in grad school the mere mention of p value will give us negative points in exams!.
2
0
9
☀️Day2 #ELIXR conference - patient-centered discussions in the morning. @pompili_cecilia presenting the dire needs and challenges of obtaining comprehensive assessment of QOL/PRO.
0
2
5
✅👍🏻Day1 of ELIXR25 - stellar lineup of speakers and panelists!. As a clinical trialist focusing on metastatic lung cancer/biomarkers, this conference has been truly informative! 👋🏻👋🏻👋🏻. Looking forward to Day2!!!
0
5
15
Kicking off our annual HN Wharton/Elia Day lecture series with an inspiring talk by @imrtlee @MSKCancerCenter. Grateful for the generous support from the donors and patient volunteers. @thePMCF
1
5
35
It is most gratifying to see talented young physicians successfully complete their residency/fellowship training. Congratulations to our new graduates!. @ldawsonmd
2
5
21
RT @pmcancercentre: Together, we raised $20.61 million to support life-saving cancer research and patient care! . Congratulations and thank….
0
9
0
📕It was a fantastic experience working with @BenjaminKannMD @anantm et al on this emerging topic. Free access paper here 👉 @ASCO_pubs
Thrilled to share new @ASCO Educational Book Chapter! 📖🤖.AI for head & neck cancer—diagnosis to personalized treatment. 🔹 Better tumor diagnosis & prognosis.🔹 Multimodal AI for survival prediction.🔹 Early toxicity & complication detection.Paper:
0
2
10
🎓🩺🩻Every year we welcome & bid farewell to fellows at our palliative RT & oligomet program (PROP). It’s hardest to say goodbye this yr. In addition to 3 excellent graduating fellows, we’ll miss the one and only Dr. Cummings, @JoannaJavor, & Ed Taylor! Wishing them the best! 💝
0
2
15
RT @oncologytube: 🌟 Tarlatamab Phase 3 Results at ASCO 2025! NEW SOC?.📊mOS: 13.6 months vs 8.3 months (chemo), HR=0.6, p<0.001.💡 27% vs 62%….
0
6
0
🌟Worth noting that it's "structured" exercise, not just telling patients to exercise (which was the control arm). Just imagine the effort and perseverance of all involved. 👏👏👏.@CDNCancerTrials @QueensuSCRI @GICancer @GillSharlene @NEJM @ASCO @RebeccaKSWong
A standing ovation for #CHALLENGE trial at #ASCO25 - first in world to definitively show exercise reduces recurrence and improves survival:. “For every 16 people, exercise prevents 1 person from recurrent/new cancer”. “For every 14 people, exercise prevents 1 person from dying”
2
2
9
A stellar panel of experts!.
Our #SABRCAN25 OMD Session!. @_ShankarSiva @PeterMacCC & @safaviaa @MSKCancerCenter - From Complexity to Clarity: Tackling Difficult OMD Cases. Panelists:.@ldawsonmd .Suresh Senan.@HoudaBahig .@Dan_ChangMD .Melanie Davidson.@DrewMoghanaki.@emmadunne .@DrAlexLouie.Alanah Bergman
0
1
2
⏰🚨👏ReACT1.0 #ASCO25 @HeadNeckMD @jdschoenfeld1 @MargalitMd @DrHaddadRobert . 🌟 Ph2, stage I-III HPV+ OPC.🌟54-66Gy gross dz based on risk/DNA clearance.🌟30-54Gy elective.🌟~60%>95% clearance at wk 4-5.🌟2yr PFS 90% - 5 events (1 death): 3LRR, 4DM
2
3
15
🏳️🌈🏳️⚧️ Happy Pride Month!!!.Air Canada 🇨🇦 is doing this right. 👋👋👋.
Our first all-2SLGBTQIA+ flight was a heartfelt celebration reflecting our unwavering commitment to inclusivity and equality, in the air and on the ground.
0
0
0
RT @StephenVLiu: #ASCO25 Dr. @charlesrudin presents interim analysis of DeLLphi-304: randomized phase II study of tarlatamab (DLL3 TCE) vs….
0
39
0
🖥️💡Made a (very rough) summary of some avail ctDNA assays ahead of many #ASCO25 presentations. to be elaborated later. 🤞
0
0
6